, Shyam Vedantam2
, Sunil Amin2
, Sean Bhalla2
, Jodie A. Barkin2
, Mahmoud Mahfouz2
, Shria Kumar2
1Department of Medicine, Jackson Memorial Hospital, University of Miami, Miami, FL, USA
2Division of Digestive Health and Liver Diseases, Department of Medicine, University of Miami, Miami, FL, USA
© 2026 Korean Society of Gastrointestinal Endoscopy
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Ethical Statements
Not applicable.
Conflicts of Interest
Sunil Amin is a consultant for Boston Scientific. The other authors have no potential conflicts of interest.
Funding
None.
Author Contributions
Conceptualization: RSB, SV; Data curation: RSB, SV; Formal analysis: RSB, SV; Methodology: RSB, SV; Visualization: RSB, SV; Supervision: SA, SB, JAB, MM, SK; Writing–original draft: RSB, SV; Writing–review & editing: SA, SB, JB, MM, SK.
| Study | Year | Country | Study size (n) | Design | PS (n) | MS (n) | Male (%) | Age (yr, median or mean±SD) | Follow-up endpoint | Follow-up (day) | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PS | MS | PS | MS | PS | MS | PS | MS | |||||||
| Okuno et al.23 | 2023 | Japan | 76 | Retrospective cohort | 38 | 38 | 60 | 53 | Median | Median | Death | Death | 871 | 1,116 |
| Paik et al.22 | 2024 | Korea | 50 | Randomized controlled trial | 25 | 25 | 60 | 56 | 70.4±9.7 | 71.6±9.8 | Recurrent biliary obstruction | Recurrent biliary obstruction | 270 | 270 |
| Kim et al.24 | 2021 | Korea | 102 | Retrospective cohort | 67 | 35 | 60 | 69 | Median | Median | Cholangitis, death | Cholangitis, death | 365 | 365 |
| Xia et al.25 | 2021 | China | 262 | Retrospective cohort | 96 | 96 | 60 | 54 | 64±12.2 | 65.8±13.0 | Death | Death | 900 | 900 |
| Study | Etiology of MHBO |
|---|---|
| Okuno et al.23 | Biliary tract cancer (54/76) |
| Metastatic cancer, other site (17/76) | |
| Hepatocellular carcinoma (5/76) | |
| Paik et al.22 | Cholangiocarcinoma (42/50) |
| Gallbladder cancer (6/50) | |
| Metastatic cancer, other site (2/50) | |
| Kim et al.24 | Cholangiocarcinoma (102/102) |
| Xia et al.25 | Cholangiocarcinoma (171/262) |
| Gallbladder cancer (47/262) | |
| Hepatocellular carcinoma (27/262) | |
| Metastatic cancer, other site (17/262) |
| Study | PS | MS |
|---|---|---|
| Okuno et al.23 | 7 Fr, variable length | Niti-S large cell D-type biliary stent, Bonastent M-hilar, HILZO stent, BileRush, Zilver 635 stent, Zeo stent, and JOSTENT SelfX stent, Hanarostent. All self-expanding MS were 8 mm or 10 mm in diameter. Placed either partially stent-in-stent or side by side. |
| Paik et al.22 | 7 Fr straight (Cotton-Leung Biliary Stent) or double pigtail (Zimmon Biliary stent), variable length 10–15 cm | Fully covered COMVI II stent. All self-expanding MS were 6 mm in diameter. Placed side by side. |
| Kim et al.24 | NR | Uncovered self-expandable MS. |
| Xia et al.25 | 7–10 F (Boston Scientific Matrik; Cook Medical) 12–18 cm in length | Uncovered self-expandable MS. Boston Scientific or MicroTech. 6–8 mm in diameter and 8–12 cm in length. |
| Study | Study size (n) | Design | Technical success (n) | Clinical success (n) | Adverse event (n) | Post-procedure cholangitis (n) | Recurrence (n) | Endoscopic reintervention (n) | External (percutaneous) drainage (n) | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PS | MS | PS | MS | PS | MS | PS | MS | PS | MS | PS | MS | PS | MS | |||
| Okuno et al.23,a) | 76 | Retrospective cohort | 38 | 37 | 37 | 37 | 2 | 6 | 20 | 19 | 20 | 19 | 20 | 19 | 0 | 3 |
| Paik et al.22 | 50 | Randomized controlled trial | 25 | 25 | 19 | 22 | 8 | 8 | 6 | 5 | 16 | 10 | NR | NR | 1 | 1 |
| Kim et al.24 | 102 | Retrospective cohort | 67 | 35 | 44 | 25 | NR | NR | NR | NR | NR | NR | 38 | 14 | 19 | 8 |
| Xia et al.25 | 192 | Retrospective cohort | 96 | 96 | 69 | 95 | 20 | 4 | 25 | 7 | 51 | 35 | 96 | 29 | NR | NR |
| PS event (n) | MS event (n) | OR (95% CI) | p-value | |
|---|---|---|---|---|
| Clinical success | 169/226 | 179/194 | 0.32 (0.07–1.55) | 0.16 |
| Technical success | 226/226 | 193/194 | 3.08 (0.12–78.02) | 0.50 |
| Adverse events | 30/159 | 18/159 | 1.32 (0.25–7.09) | 0.75 |
| Post-procedure cholangitis | 51/159 | 31/160 | 1.96 (0.77–4.97) | 0.16 |
| Recurrent obstruction | 87/159 | 64/159 | 1.79 (1.15–2.81) | 0.01a) |
| Endoscopic reintervention | 154/201 | 62/169 | 6.56 (0.52–82.08) | 0.14 |
| Percutaneous drainage | 20/130 | 12/98 | 1.01 (0.37–2.73) | 0.98 |
| Study | Year | Country | Study size (n) | Design | PS (n) | MS (n) | Male (%) | Age (yr, median or mean±SD) | Follow-up endpoint | Follow-up (day) | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PS | MS | PS | MS | PS | MS | PS | MS | |||||||
| Okuno et al.23 | 2023 | Japan | 76 | Retrospective cohort | 38 | 38 | 60 | 53 | Median | Median | Death | Death | 871 | 1,116 |
| Paik et al.22 | 2024 | Korea | 50 | Randomized controlled trial | 25 | 25 | 60 | 56 | 70.4±9.7 | 71.6±9.8 | Recurrent biliary obstruction | Recurrent biliary obstruction | 270 | 270 |
| Kim et al.24 | 2021 | Korea | 102 | Retrospective cohort | 67 | 35 | 60 | 69 | Median | Median | Cholangitis, death | Cholangitis, death | 365 | 365 |
| Xia et al.25 | 2021 | China | 262 | Retrospective cohort | 96 | 96 | 60 | 54 | 64±12.2 | 65.8±13.0 | Death | Death | 900 | 900 |
| Study | Etiology of MHBO |
|---|---|
| Okuno et al.23 | Biliary tract cancer (54/76) |
| Metastatic cancer, other site (17/76) | |
| Hepatocellular carcinoma (5/76) | |
| Paik et al.22 | Cholangiocarcinoma (42/50) |
| Gallbladder cancer (6/50) | |
| Metastatic cancer, other site (2/50) | |
| Kim et al.24 | Cholangiocarcinoma (102/102) |
| Xia et al.25 | Cholangiocarcinoma (171/262) |
| Gallbladder cancer (47/262) | |
| Hepatocellular carcinoma (27/262) | |
| Metastatic cancer, other site (17/262) |
| Study | PS | MS |
|---|---|---|
| Okuno et al.23 | 7 Fr, variable length | Niti-S large cell D-type biliary stent, Bonastent M-hilar, HILZO stent, BileRush, Zilver 635 stent, Zeo stent, and JOSTENT SelfX stent, Hanarostent. All self-expanding MS were 8 mm or 10 mm in diameter. Placed either partially stent-in-stent or side by side. |
| Paik et al.22 | 7 Fr straight (Cotton-Leung Biliary Stent) or double pigtail (Zimmon Biliary stent), variable length 10–15 cm | Fully covered COMVI II stent. All self-expanding MS were 6 mm in diameter. Placed side by side. |
| Kim et al.24 | NR | Uncovered self-expandable MS. |
| Xia et al.25 | 7–10 F (Boston Scientific Matrik; Cook Medical) 12–18 cm in length | Uncovered self-expandable MS. Boston Scientific or MicroTech. 6–8 mm in diameter and 8–12 cm in length. |
| Study | Study size (n) | Design | Technical success (n) | Clinical success (n) | Adverse event (n) | Post-procedure cholangitis (n) | Recurrence (n) | Endoscopic reintervention (n) | External (percutaneous) drainage (n) | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PS | MS | PS | MS | PS | MS | PS | MS | PS | MS | PS | MS | PS | MS | |||
| Okuno et al.23, |
76 | Retrospective cohort | 38 | 37 | 37 | 37 | 2 | 6 | 20 | 19 | 20 | 19 | 20 | 19 | 0 | 3 |
| Paik et al.22 | 50 | Randomized controlled trial | 25 | 25 | 19 | 22 | 8 | 8 | 6 | 5 | 16 | 10 | NR | NR | 1 | 1 |
| Kim et al.24 | 102 | Retrospective cohort | 67 | 35 | 44 | 25 | NR | NR | NR | NR | NR | NR | 38 | 14 | 19 | 8 |
| Xia et al.25 | 192 | Retrospective cohort | 96 | 96 | 69 | 95 | 20 | 4 | 25 | 7 | 51 | 35 | 96 | 29 | NR | NR |
| PS event (n) | MS event (n) | OR (95% CI) | p-value | |
|---|---|---|---|---|
| Clinical success | 169/226 | 179/194 | 0.32 (0.07–1.55) | 0.16 |
| Technical success | 226/226 | 193/194 | 3.08 (0.12–78.02) | 0.50 |
| Adverse events | 30/159 | 18/159 | 1.32 (0.25–7.09) | 0.75 |
| Post-procedure cholangitis | 51/159 | 31/160 | 1.96 (0.77–4.97) | 0.16 |
| Recurrent obstruction | 87/159 | 64/159 | 1.79 (1.15–2.81) | 0.01 |
| Endoscopic reintervention | 154/201 | 62/169 | 6.56 (0.52–82.08) | 0.14 |
| Percutaneous drainage | 20/130 | 12/98 | 1.01 (0.37–2.73) | 0.98 |
SD, standard deviation; PS, plastic stent; MS, metal stent.
MHBO, malignant hilar biliary obstruction.
PS, plastic stent; MS, metal stent; NR, not reported.
PS, plastic stent; MS, metal stent; NR, not reported. Propensity score matching explains the discrepancy between n=76 with 38 PS and 37 MS.
PS, plastic stent; MS, metal stent; OR, odds ratio; CI, confidence interval. Statistically significant difference. The
